Canonically, BRCA mutant cancers are considered acutely sensitive to PARP inhibition as unrepaired lesions destabilise replication forks and/or develop into DNA double-strand breaks (DSBs) over the course of the cell cycle [3,5]. This evidence concerns the gene PARP1 and cancer.